Abbott Gets CE Mark for Dual Glucose-Ketone Sensor, Declares Dividend

Abbott Laboratories (ABT) declared a quarterly dividend of $0.63 per share, payable on August 17, 2026, to shareholders of record on July 15. This marks the company's 410th consecutive quarterly payout since 1924.

Concurrently, Abbott secured CE Mark for its Libre Duo dual glucose-ketone sensor and expanded a commercialization agreement with MiniMed. The new sensor targets diabetic ketoacidosis (DKA) risks, a serious condition highlighted in recent company-backed studies.

The Product

Libre Duo is a wearable device that continuously measures both glucose and ketone levels. It aims to help Type 1 diabetes patients avoid DKA by providing early alerts when ketone levels rise.

Pricing and Availability

Abbott has not yet disclosed pricing or a commercial launch date for CE Mark markets. It is expected to be available initially in Europe before global expansion.

Competition

Libre Duo faces competition from other continuous glucose monitors (CGM) like Dexcom G7 and Medtronic Guardian. However, its dual ketone measurement feature may give it an edge in the DKA-prone patient segment.

Potential Impact on the Company

The new product is expected to boost revenue for Abbott's diabetes unit, which constitutes a significant portion of its business. The expanded MiniMed deal may also increase market share in integrated insulin delivery systems.